Preview

Кардиология

Расширенный поиск

Баланс пользы и риска при назначении антитромботической терапии у больных ишемической болезнью сердца. Как относиться к проблеме желудочно-кишечных кровотечений?

https://doi.org/10.18087/cardio.2020.7.n1159

Полный текст:

Аннотация

Обзор посвящен проблеме кровотечений из верхних отделов желудочно-кишечного тракта у больных ишемической болезнью сердца (ИБС), получающих антитромботическую терапию. Подробно рассмотрены подходы к стратификации риска желудочно-кишечных кровотечений и коррекции модифицируемых факторов, определяющих вероятность развития данных событий. Даны рекомендации по назначению препаратов для защиты желудка. Подчеркивается взаимосвязь факторов риска тромбозов и кровотечений и обсуждаются возможные показания для многокомпонентного антитромботического лечения у больных стабильной ИБС.

Об авторах

А. Л. Комаров
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РФ, Москва, Россия
Россия
д. м. н, ведущий научный сотрудник отдела клинических проблем атеротромбоза


О. О. Шахматова
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РФ, Москва, Россия
Россия
к. м. н., младший научный сотрудник отдела клинических проблем атеротромбоза


В. В. Коробкова
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РФ, Москва, Россия
Россия
аспирант отдела клинических проблем атеротромбоза


Список литературы

1. Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations from the International Consensus Group. Annals of Internal Medicine. 2019;171(11):805–22. DOI: 10.7326/M19-1795

2. Gralnek I, Dumonceau J-M, Kuipers E, Lanas A, Sanders D, Kurien M et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1–46. DOI: 10.1055/s-0034-1393172

3. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678):1849–60. DOI: 10.1016/S0140-6736(09)60503-1

4. Sehested TSG, Carlson N, Hansen PW, Gerds TA, Charlot MG, TorpPedersen C et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European Heart Journal. 2019;40(24):1963–70. DOI: 10.1093/eurheartj/ehz104

5. Khan MY, Siddiqui WJ, Alvarez C, Aggarwal S, Hasni SF, Ahmad A et al. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. 2018;30(8):847–53. DOI: 10.1097/MEG.0000000000001125

6. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. MetaAnalysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients with Atrial Fibrillation. The American Journal of Cardiology. 2012;110(3):453– 60. DOI: 10.1016/j.amjcard.2012.03.049

7. Girardin M, Bertolini D, Ditisheim S, Frossard J-L, Giostra E, Goossens N et al. Use of glasgow-blatchford bleeding score reduces hospital stay duration and costs for patients with low-risk upper GI bleeding. Endoscopy International Open. 2014;02(02):E74–9. DOI: 10.1055/s-0034-1365542

8. Panchenko E.P., Komarov A.L., Shakhmatova O.O., Yarovaya E.B., Shuleshova A.G. Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients with Chronic Coronary Syndromes. № NCT04347200. [Av. at: https://clinicaltrials.gov/ct2/show/NCT04347200].2020.

9. Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD et al. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). The American Journal of Cardiology. 2018;122(10):1638–46. DOI: 10.1016/j.amjcard.2018.07.041

10. Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. New England Journal of Medicine. 2017;377(5):431–41. DOI: 10.1056/NEJMoa1707278

11. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2019;380(14):1326–35. DOI: 10.1056/NEJMoa1814051

12. Halvorsen S, Storey RF, Rocca B, Sibbing D, ten Berg J, Grove EL et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal. 2016;38(19):1455–62. DOI: 10.1093/eurheartj/ehw454

13. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267–315. DOI: 10.1093/eurheartj/ehv320

14. Jensen BES, Hansen JM, Larsen KS, Junker AB, Lassen JF, Jensen SE et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. European Journal of Gastroenterology & Hepatology. 2017;29(10):1118–25. DOI: 10.1097/MEG.0000000000000934

15. Bouhoutsos J, Barabas AP, Martin P. Arteriosclerosis, amputation and peptic ulcer. Postgraduate Medical Journal. 1972;48(565):671–2. DOI: 10.1136/pgmj.48.565.671

16. Jolobe OMP. The Association of Peptic Ulcer Disease and Abdominal Aortic Aneurysm. The American Journal of Medicine. 2019;132(9):e724. DOI: 10.1016/j.amjmed.2019.03.047

17. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165. DOI: 10.1093/eurheartj/ehy394

18. Lip GYH, Collet J-P, Haude M, Byrne R, Chung EH, Fauchier L et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Europace. 2019;21(2):192– 3. DOI: 10.1093/europace/euy174

19. Crowe SE. Helicobacter pylori Infection. New England Journal of Medicine. 2019;380(12):1158–65. DOI: 10.1056/NEJMcp1710945

20. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology. 2017;112(2):212–39. DOI: 10.1038/ajg.2016.563

21. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. DOI: 10.1136/gutjnl-2016-312288

22. El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology. 2018;16(7):992-1002.e6. DOI: 10.1016/j.cgh.2018.03.013

23. Parker WAE, Storey RF. Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal. 2019;40(24):1971–4. DOI: 10.1093/eurheartj/ehz102

24. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine. 2017;37:19–24. DOI: 10.1016/j.ejim.2016.10.007

25. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety. 2019;10:204209861880992. DOI: 10.1177/2042098618809927

26. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients with Coronary Artery Disease: A Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22(2):142–52. DOI: 10.1177/1074248416663647

27. Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FYB, El-Hayek G et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248. DOI: 10.1136/openhrt-2015-000248

28. FDA. Postmarket Drug Safety Information for Patients and Providers. Information on Clopidogrel Bisulfate (marketed as Plavix). 2010. [Internet] 2010. Available at: http://wayback.archive-it.org/7993/20170111075953/http:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm

29. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine. 2010;363(20):1909–17. DOI: 10.1056/NEJMoa1007964

30. Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials. Journal of the American Heart Association. 2013;2(1):e004564. DOI: 10.1161/JAHA.112.004564

31. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017;377(14):1319–30. DOI: 10.1056/NEJMoa1709118

32. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, DoubleBlind, Placebo-Controlled Trial. Gastroenterology. 2019;157(2):403- 412.e5. DOI: 10.1053/j.gastro.2019.04.041

33. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, FunckBrentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425

34. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2019;41(4):543–603. DOI: 10.1093/eurheartj/ehz405

35. Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GYH. Anticoagulant-related gastrointestinal bleeding –could this facilitate early detection of benign or malignant gastrointestinal lesions? Annals of Medicine. 2014;46(8):672–8. DOI: 10.3109/07853890.2014.952327

36. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG et al. M nd Treatment of Cardiovascular Risk Factors in Outpatients with Atherothrombosis. JAMA. 2006;295(2):180–9. DOI: 10.1001/jama.295.2.180

37. Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B et al. Association of Multiple Enrichment Criteria with Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. Journal of the American College of Cardiology. 2019;73(25):3281–91. DOI: 10.1016/j.jacc.2019.04.046


Для цитирования:


Комаров А.Л., Шахматова О.О., Коробкова В.В. Баланс пользы и риска при назначении антитромботической терапии у больных ишемической болезнью сердца. Как относиться к проблеме желудочно-кишечных кровотечений? Кардиология. 2020;60(7):115-124. https://doi.org/10.18087/cardio.2020.7.n1159

For citation:


Komarov A.L., Shakhmatova O.O., Korobkova V.V. The balance of benefit and risk in prescribing antithrombotic therapy for patients with coronary artery disease. How to deal with the gastrointestinal bleeding problem? Kardiologiia. 2020;60(7):115-124. (In Russ.) https://doi.org/10.18087/cardio.2020.7.n1159

Просмотров: 179


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)